Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Nyxoah Sa (NYXH)
:NYXH
NYXH Stock Chart & Stats
Day’s Range― - ―
52-Week Range$6.76 - $20.00
Previous CloseN/A
Volume100.61K
Average Volume (3M)43.07K
Market Cap
$356.96M
Enterprise Value$241.15M
Total Cash (Recent Filing)10.11M
Total Debt (Recent Filing)4.87M
Price to Earnings (P/E)―
Beta0.77
Next Earnings
Mar 13, 2025EPS Estimate
-0.49Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.86
Shares Outstanding34,386,765
10 Day Avg. Volume38,503
30 Day Avg. Volume43,071
Standard Deviation0.26
R-Squared0.07
Alpha-0.00791
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)98.71
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$16.09Price Target Upside47.48% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
---
Nyxoah News
PremiumCompany Announcements
Nyxoah Launches Genio Therapy in Middle East with First UAE Implantation
PremiumCompany Announcements
Nyxoah Receives Transparency Notification from BlackRock
PremiumCompany Announcements
Nyxoah Receives Transparency Notification from BlackRock, Inc.
PremiumCompany Announcements
Nyxoah Launches Genio System in England for OSA
PremiumCompany Announcements
Nyxoah Updates Share Capital and Voting Rights
PremiumCompany Announcements
Nyxoah to Present at Healthcare Conference Amidst Growth---
Bulls Say, Bears Say
Bulls Say
Financial HealthNyxoah reported a proforma cash position of €95.6M, indicating strong financial health.
Market ExpansionThe commercial launch of Genio in England with its first implants successfully performed highlights Nyxoah's expansion in the European market.
Market Share GrowthGenio’s overall market share increased to 25% in 3Q24 from 21% in 2Q24, showing growth in market presence.
Bears Say
European Market ChallengesThe European market will continue to be difficult to grow and penetrate, posing a challenge for Nyxoah's expansion efforts in that region.
Regulatory DelaysThere is a delay in the Belgium facility inspection, which is expected to push US approval to the first quarter of 2025.
Revenue ShortfallThird-quarter revenue of €1.3M was below expectations, although focus remains on entering the US market.
---
Ownership Overview
11.80%
Insiders
5.54% Mutual Funds
9.10% Other Institutional Investors
73.53% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
NYXH FAQ
What was Nyxoah Sa’s price range in the past 12 months?
Nyxoah Sa lowest stock price was $6.76 and its highest was $20.00 in the past 12 months.
What is Nyxoah Sa’s market cap?
Nyxoah Sa’s market cap is $356.96M.
When is Nyxoah Sa’s upcoming earnings report date?
Nyxoah Sa’s upcoming earnings report date is Mar 13, 2025 which is in 18 days.
How were Nyxoah Sa’s earnings last quarter?
Nyxoah Sa released its earnings results on Nov 06, 2024. The company reported -$0.52 earnings per share for the quarter, missing the consensus estimate of -$0.476 by -$0.044.
Is Nyxoah Sa overvalued?
According to Wall Street analysts Nyxoah Sa’s price is currently Undervalued.
Does Nyxoah Sa pay dividends?
Nyxoah Sa does not currently pay dividends.
What is Nyxoah Sa’s EPS estimate?
Nyxoah Sa’s EPS estimate is -0.49.
How many shares outstanding does Nyxoah Sa have?
Nyxoah Sa has 34,386,765 shares outstanding.
What happened to Nyxoah Sa’s price movement after its last earnings report?
Nyxoah Sa reported an EPS of -$0.52 in its last earnings report, missing expectations of -$0.476. Following the earnings report the stock price went down -3.6%.
Which hedge fund is a major shareholder of Nyxoah Sa?
Currently, no hedge funds are holding shares in NYXH
---
Nyxoah Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$16.09 (47.48% Upside)
$16.09 (47.48% Upside)
Blogger Sentiment
Bullish
NYXH Sentiment 70%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 253.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 4.3%
Last 30 Days ▼ 11.5%
Last 30 Days ▼ 11.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-32.15%
12-Months-Change
Fundamentals
Return on Equity
-49.39%
Trailing 12-Months
Asset Growth
11.80%
Trailing 12-Months
Company Description
Nyxoah Sa
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep disordered breathing conditions. Nyxoah's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.
---
NYXH Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a positive outlook with strong clinical trial results, significant regulatory progress, and successful capital raising efforts. However, there are challenges related to increased operational losses, FDA inspection delays, and uncertainties in reimbursement strategies.Read More>---
NYXH Stock 12 Month Forecast
Average Price Target
$16.09
▲(47.48% Upside)
Technical Analysis
Irhythm Technologies
―
Inspire Medical Systems
―
Senseonics Holdings
―
Stereotaxis
―
NovoCure
―
Smith & Nephew Snats
―
Best Analysts Covering NYXH
1 Year
1 Year Success Rate
13/15 ratings generated profit
1 Year Average Return
+26.69%
reiterated a buy rating 2 months ago
Copying Edward White's trades and holding each position for 1 Year would result in 86.67% of your transactions generating a profit, with an average return of +26.69% per trade.
---